Bausch Health Says Board Authorized Management To Explore Potential Sale Of Subsidiary Bausch + Lomb; Says Process Is Ongoing. No Decision Has Been Reached
Bausch Health Says Board Authorized Management To Explore Potential Sale Of Subsidiary Bausch + Lomb; Says Process Is Ongoing. No Decision Has Been Reached
The company issued the following statement in response to a request from the Canadian Investment Regulatory Organization (CIRO):
公司就加拿大投資監管機構（CIRO）的請求發佈了以下聲明：
"As previously disclosed, the Company believes that completing the full separation of its subsidiary, Bausch + Lomb, makes strategic sense. The Bausch Health Board of Directors authorized management and management of its subsidiary, Bausch + Lomb, to explore a potential sale, which is one of several options being considered to complete the separation. That process is ongoing. No decision has been reached to proceed with any particular transaction, and there can be no assurance that it will result in a transaction."
"正如之前披露的，公司相信完整分離其子公司Bausch + Lomb是具有戰略意義的。Bausch Health董事會授權管理層及其子公司Bausch + Lomb的管理層探索潛在的出售，這是完成分離的幾個期權之一。該過程正在進行中。尚未達成推進任何特定交易的決定，因此無法保證會導致任何交易的達成。"
譯文內容由第三人軟體翻譯。
